Abstract
Objectives Assessment of age, sex and smoking-specific risk of cancer diagnosis and non-cancer mortality following primary care consultation for 15 new-onset symptoms.
Methods and analysis Data on patients aged 18-99 in 2007 – 2017 were extracted from a UK primary care database (CPRD Gold), comprising a randomly-selected reference group and a symptomatic cohort of patients presenting with one of 15 new onset symptoms (abdominal pain, abdominal bloating, rectal bleed, change in bowel habit, dyspepsia, dysphagia, dyspnoea, haemoptysis, haematuria, fatigue, night sweats, weight loss, jaundice, breast lump, post-menopausal bleed).
Time-to-event models were used to estimate outcome-specific hazards for site-specific cancer diagnosis and non-cancer mortality, and used to estimate cumulative incidence up to 12 months following index consultation.
Results Data included 1,622,419 patients, of whom 36,802 had a cancer diagnosis and 28,857 died without a cancer diagnosis within 12 months of index.
Risk of specific cancers exceeded the UK urgent referral risk threshold of 3% from a relatively young age for patients with red flag symptoms. For non-organ-specific symptoms, the risk of individual cancer sites either did not reach the threshold at any age, or reached it only in older patients.
Conclusion Patients with new-onset symptoms in primary care often have comparable risk of cancer diagnosis and of non-cancer mortality. A holistic approach to risk assessment that includes the risk of different cancer types alongside mortality risk, especially among older patients, is needed to inform management of symptomatic patients in primary care, particularly for patients with non-organ-specific symptoms.
What is already known on this topic
Evidence describing the diagnostic value of symptoms for cancer can help to assess which patients who present to primary care need urgent specialist assessment
Current evidence is limited as age is often handled categorically, smoking status is not taken into account and study periods are historical.
Further, evidence is concentrated on assessing the risk of specific cancer sites, although the same symptom can be related to cancer of different organs.
What this study adds
We present evidence on age-, sex-, and smoking status-specific estimates of risk of cancer of different organs and overall, alongside estimates of non-cancer death.
Estimates relate to patients who present with one of 15 possible cancer symptoms, from a relatively recent time period.
Certain symptoms such as jaundice and dysphagia are associated with high risk of non-cancer death in older patients.
Other symptoms, such as unintended weight loss, fatigue and abdominal pain, are associated with excess risk of a range of different cancers, and such evidence can guide the choice of diagnostic strategies and the design of multi-cancer diagnostic services.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at http://www.icmje.org/disclosure-of-interest/ and declare: no support from any organisation for the submitted work; MB has received personal fees from Grail Inc for membership of an Independent Data Monitoring Committee; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
The work was supported by the International Alliance for Cancer Early Detection, a partnership between Cancer Research UK (C18081/A31373), Canary Center at Stanford University, the University of Cambridge, OHSU Knight Cancer Institute, University College London, and the University of Manchester. SI is additionally supported by Cancer Research UK (EDDPMA-May22\100062) and HH and MB by CRUK International Alliance for Cancer Early Detection (ACED) Pathway Awards (EDDAPA-2022/100001 and EDDAPA-2022/100002, respectively). GL was supported by a Cancer Research UK (C18081/A18180) Advanced Clinician Scientist Fellowship. CR acknowledges funding from Cancer Research UK Early Detection and Diagnosis Committee (grant number EDDCPJT\100018). JUS is supported by a National Institute of Health Research Advanced Fellowship (NIHR300861). ACA is support by Cancer Research UK grant: PPRPGM-Nov20\100002. SI, AW and ACA are supported by the National Institute for Health and Care Research (NIHR) Cambridge Biomedical Research Centre (BRC-1215-20014; NIHR203312) [*]. AW is part of the BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No 116074. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. All authors had access to statistical reports, tables, and analysis code. MB, CR, BW, SI and GL had full access to all of the data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Independent Scientific Advisory Committee of the UK Medicines and Healthcare products Regulatory Agency gave ethical approval for this work (ISAC Protocol number 18_299), under Section 251 of the NHS Social Care Act 2006.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in BMJ editions and any other BMJPGL products and sublicences such use and exploit all subsidiary rights, as set out in our licence.
Figure 1 added. Table 2 revised.
Data Availability
Potential concerns around patient confidentiality prevent open sharing of the underlying data for this study. CPRD Gold data can be obtained from CPRD, subject to protocol approval via CPRD's Research Data Governance Process. Further details can be found at https://cprd.com/data-access. Data extraction and analysis code are available at https://github.com/MattEBarclay/cprd_symptom_cancer_1.
